RU2010150934A - Пероральный препарат - Google Patents
Пероральный препарат Download PDFInfo
- Publication number
- RU2010150934A RU2010150934A RU2010150934/15A RU2010150934A RU2010150934A RU 2010150934 A RU2010150934 A RU 2010150934A RU 2010150934/15 A RU2010150934/15 A RU 2010150934/15A RU 2010150934 A RU2010150934 A RU 2010150934A RU 2010150934 A RU2010150934 A RU 2010150934A
- Authority
- RU
- Russia
- Prior art keywords
- angiogenin
- muscular dystrophy
- dystrophy
- muscle
- syndrome
- Prior art date
Links
- 229940126701 oral medication Drugs 0.000 title 1
- 102100022987 Angiogenin Human genes 0.000 claims abstract 13
- 108010072788 angiogenin Proteins 0.000 claims abstract 13
- 238000000034 method Methods 0.000 claims abstract 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract 8
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract 6
- 201000000585 muscular atrophy Diseases 0.000 claims abstract 6
- 201000006938 muscular dystrophy Diseases 0.000 claims abstract 6
- 102000004877 Insulin Human genes 0.000 claims abstract 4
- 108090001061 Insulin Proteins 0.000 claims abstract 4
- 208000010316 Myotonia congenita Diseases 0.000 claims abstract 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract 4
- 230000001419 dependent effect Effects 0.000 claims abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 4
- 229940125396 insulin Drugs 0.000 claims abstract 4
- 230000020763 muscle atrophy Effects 0.000 claims abstract 4
- 206010028417 myasthenia gravis Diseases 0.000 claims abstract 4
- 230000001314 paroxysmal effect Effects 0.000 claims abstract 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract 4
- 208000011580 syndromic disease Diseases 0.000 claims abstract 4
- 208000001132 Osteoporosis Diseases 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 208000035475 disorder Diseases 0.000 claims abstract 3
- 210000003205 muscle Anatomy 0.000 claims abstract 3
- 206010003694 Atrophy Diseases 0.000 claims abstract 2
- 206010006895 Cachexia Diseases 0.000 claims abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 2
- 208000029323 Congenital myotonia Diseases 0.000 claims abstract 2
- 208000035810 Denervation atrophy Diseases 0.000 claims abstract 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims abstract 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims abstract 2
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract 2
- 208000029578 Muscle disease Diseases 0.000 claims abstract 2
- 208000021642 Muscular disease Diseases 0.000 claims abstract 2
- 206010028424 Myasthenic syndrome Diseases 0.000 claims abstract 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims abstract 2
- 208000008589 Obesity Diseases 0.000 claims abstract 2
- 206010033799 Paralysis Diseases 0.000 claims abstract 2
- 208000026062 Tissue disease Diseases 0.000 claims abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract 2
- 210000000577 adipose tissue Anatomy 0.000 claims abstract 2
- 230000037444 atrophy Effects 0.000 claims abstract 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims abstract 2
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims abstract 2
- 201000011474 congenital myopathy Diseases 0.000 claims abstract 2
- 201000009338 distal myopathy Diseases 0.000 claims abstract 2
- 201000001421 hyperglycemia Diseases 0.000 claims abstract 2
- 208000014674 injury Diseases 0.000 claims abstract 2
- 208000030159 metabolic disease Diseases 0.000 claims abstract 2
- 208000018360 neuromuscular disease Diseases 0.000 claims abstract 2
- 235000020824 obesity Nutrition 0.000 claims abstract 2
- 206010030875 ophthalmoplegia Diseases 0.000 claims abstract 2
- 210000000056 organ Anatomy 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims abstract 2
- 230000000750 progressive effect Effects 0.000 claims abstract 2
- 230000000306 recurrent effect Effects 0.000 claims abstract 2
- 208000001076 sarcopenia Diseases 0.000 claims abstract 2
- 230000008733 trauma Effects 0.000 claims abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract 2
- 102000016970 Follistatin Human genes 0.000 claims 5
- 108010014612 Follistatin Proteins 0.000 claims 5
- 239000006186 oral dosage form Substances 0.000 claims 3
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000009693 chronic damage Effects 0.000 claims 1
- 235000020247 cow milk Nutrition 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 claims 1
- 235000018343 nutrient deficiency Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008902371A AU2008902371A0 (en) | 2008-05-14 | Oral preparation | |
| AU2008902371 | 2008-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010150934A true RU2010150934A (ru) | 2012-06-20 |
Family
ID=41318285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010150934/15A RU2010150934A (ru) | 2008-05-14 | 2009-05-14 | Пероральный препарат |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110262422A1 (enExample) |
| EP (1) | EP2307044A4 (enExample) |
| JP (1) | JP2011519960A (enExample) |
| KR (1) | KR20110033122A (enExample) |
| CN (1) | CN102099050A (enExample) |
| AU (1) | AU2009246052A1 (enExample) |
| BR (1) | BRPI0911958A2 (enExample) |
| CA (1) | CA2724048A1 (enExample) |
| IL (1) | IL209284A0 (enExample) |
| MX (1) | MX2010012438A (enExample) |
| NZ (1) | NZ589306A (enExample) |
| RU (1) | RU2010150934A (enExample) |
| WO (1) | WO2009137879A1 (enExample) |
| ZA (1) | ZA201009004B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101760758B1 (ko) * | 2008-05-14 | 2017-07-24 | 애그리컬쳐 빅토리아 서비스 피티와이 엘티디 | 질병 및 장애를 치료하기 위한 안지오게닌 또는 안지오게닌 아고니스트의 이용 |
| CA2818467A1 (en) * | 2009-11-18 | 2011-05-26 | Murray Goulburn Co-Operative Co. Limited | Recombinant microorganisms |
| US20120328591A1 (en) * | 2009-11-18 | 2012-12-27 | Agriculture Victoria Services Pty Ltd | Methods for improving oral delivery |
| WO2011060489A1 (en) * | 2009-11-18 | 2011-05-26 | Murray Goulburn Co-Operative Co. Limited | Transgenic non-human animals |
| WO2011113100A1 (en) * | 2010-03-17 | 2011-09-22 | Murray Goulburn Co-Operative Co. Limited | Method of treating a bone disorder |
| AU2013204740C1 (en) * | 2012-05-10 | 2015-10-01 | Agriculture Victoria Services Pty Ltd | Methods of treating cancer using angiogenin or an angiogenin agonist |
| WO2014020676A1 (ja) * | 2012-07-31 | 2014-02-06 | 雪印メグミルク株式会社 | 新規タンパク質素材 |
| JP6140162B2 (ja) * | 2012-07-31 | 2017-05-31 | 雪印メグミルク株式会社 | 骨強化用粉乳組成物及びその製造方法 |
| AU2012386764B2 (en) * | 2012-07-31 | 2016-05-05 | Megmilk Snow Brand Co., Ltd. | Powdered milk product, and method for producing same |
| MX2015001340A (es) * | 2012-07-31 | 2015-09-04 | Megmilk Snow Brand Co Ltd | Producto novedoso de leche fermentada y metodo para preparar el mismo. |
| KR101996117B1 (ko) * | 2012-07-31 | 2019-07-03 | 유키지루시 메그밀크 가부시키가이샤 | 음료 및 그 제조 방법 |
| AU2012386761B2 (en) | 2012-07-31 | 2016-05-05 | Megmilk Snow Brand Co., Ltd. | Beverage, and method for producing same |
| KR20150036687A (ko) * | 2012-07-31 | 2015-04-07 | 유키지루시 메그밀크 가부시키가이샤 | 치즈류 및 그 제조 방법 |
| AU2012386763B2 (en) | 2012-07-31 | 2016-05-05 | Megmilk Snow Brand Co., Ltd. | Fermented milk product, and method for producing same |
| AU2012386758C1 (en) * | 2012-07-31 | 2017-03-30 | Megmilk Snow Brand Co., Ltd. | Novel protein material |
| JP2016152809A (ja) * | 2016-04-05 | 2016-08-25 | 雪印メグミルク株式会社 | 飲料及びその製造方法 |
| JP6562956B2 (ja) * | 2017-02-28 | 2019-08-21 | 雪印メグミルク株式会社 | 飲料及びその製造方法 |
| JP6357266B2 (ja) * | 2017-06-07 | 2018-07-11 | 雪印メグミルク株式会社 | 骨疾患の予防又は治療用タンパク質素材 |
| JP6357265B2 (ja) * | 2017-06-07 | 2018-07-11 | 雪印メグミルク株式会社 | 骨疾患の予防又は治療用タンパク質素材 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2947657B2 (ja) * | 1991-02-27 | 1999-09-13 | 森永乳業株式会社 | 神経成長因子産生促進剤 |
| JP3929088B2 (ja) * | 1996-06-20 | 2007-06-13 | 雪印乳業株式会社 | 骨形成促進及び骨吸収防止剤 |
| JPH10139682A (ja) * | 1996-11-14 | 1998-05-26 | Mitsubishi Chem Corp | 骨吸収促進剤 |
| CN1761463A (zh) * | 2003-03-17 | 2006-04-19 | 日本烟草产业株式会社 | 提高s－[2－([[1－(2－乙基丁基)环己基]羰基]氨基)苯基]－2－甲基丙硫代酸酯口服生物利用度的方法 |
| JP4698935B2 (ja) * | 2003-05-07 | 2011-06-08 | 雪印乳業株式会社 | 皮膚コラーゲン産生促進剤 |
| WO2004106491A2 (en) * | 2003-05-22 | 2004-12-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Angiogenin-based hiv-1 therapies |
| US20050180957A1 (en) * | 2004-01-16 | 2005-08-18 | Scharp David W. | Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells |
| GB0425625D0 (en) * | 2004-11-22 | 2004-12-22 | Royal College Of Surgeons Ie | Treatment of disease |
| WO2007023479A2 (en) * | 2005-08-23 | 2007-03-01 | Royal College Of Surgeons In Ireland | Treatment of central nervous system injury |
| US8021659B2 (en) * | 2006-04-28 | 2011-09-20 | Naidu Lp | Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof |
| US20070275036A1 (en) * | 2006-05-18 | 2007-11-29 | Celldyne Biopharma, Llc | Avian follistatin product |
| US8551547B2 (en) * | 2006-11-10 | 2013-10-08 | Murray Goulburn Co-Operative Co., Limited | Process for the preparation of angiogenin |
| KR101760758B1 (ko) * | 2008-05-14 | 2017-07-24 | 애그리컬쳐 빅토리아 서비스 피티와이 엘티디 | 질병 및 장애를 치료하기 위한 안지오게닌 또는 안지오게닌 아고니스트의 이용 |
-
2009
- 2009-05-14 WO PCT/AU2009/000602 patent/WO2009137879A1/en not_active Ceased
- 2009-05-14 NZ NZ589306A patent/NZ589306A/xx not_active IP Right Cessation
- 2009-05-14 CN CN2009801278079A patent/CN102099050A/zh active Pending
- 2009-05-14 JP JP2011508768A patent/JP2011519960A/ja active Pending
- 2009-05-14 US US12/992,416 patent/US20110262422A1/en not_active Abandoned
- 2009-05-14 BR BRPI0911958A patent/BRPI0911958A2/pt not_active Application Discontinuation
- 2009-05-14 KR KR1020107027723A patent/KR20110033122A/ko not_active Withdrawn
- 2009-05-14 CA CA2724048A patent/CA2724048A1/en not_active Abandoned
- 2009-05-14 AU AU2009246052A patent/AU2009246052A1/en not_active Abandoned
- 2009-05-14 EP EP09745301A patent/EP2307044A4/en not_active Withdrawn
- 2009-05-14 MX MX2010012438A patent/MX2010012438A/es not_active Application Discontinuation
- 2009-05-14 RU RU2010150934/15A patent/RU2010150934A/ru not_active Application Discontinuation
-
2010
- 2010-11-11 IL IL209284A patent/IL209284A0/en unknown
- 2010-12-14 ZA ZA2010/09004A patent/ZA201009004B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2724048A1 (en) | 2009-11-19 |
| EP2307044A4 (en) | 2011-10-05 |
| ZA201009004B (en) | 2012-05-30 |
| MX2010012438A (es) | 2011-06-20 |
| EP2307044A1 (en) | 2011-04-13 |
| JP2011519960A (ja) | 2011-07-14 |
| US20110262422A1 (en) | 2011-10-27 |
| WO2009137879A1 (en) | 2009-11-19 |
| BRPI0911958A2 (pt) | 2015-10-13 |
| NZ589306A (en) | 2012-11-30 |
| IL209284A0 (en) | 2011-01-31 |
| CN102099050A (zh) | 2011-06-15 |
| KR20110033122A (ko) | 2011-03-30 |
| AU2009246052A1 (en) | 2009-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010150934A (ru) | Пероральный препарат | |
| RU2010150931A (ru) | Применение ангиогенина или агонистов ангиогенина для лечения заболеваний и нарушений | |
| JP2011519960A5 (enExample) | ||
| TWI247606B (en) | Treating agent for osteopenic diseases | |
| Sakuma et al. | Sarcopenia and age‐related endocrine function | |
| Kearbey et al. | Selective androgen receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats | |
| EA011306B1 (ru) | Избирательные модуляторы андрогеновых рецепторов и способы их применения | |
| Radzki et al. | Anti-osteopenic effect of alpha-ketoglutarate sodium salt in ovariectomized rats | |
| CN108601751A (zh) | 雷公藤红素的类似物 | |
| JP2010540519A5 (enExample) | ||
| Ma et al. | Osteoporosis in patients with respiratory diseases | |
| JP2017531685A (ja) | マンモグラフィ乳房密度及び／又は乳癌リスクを低下させる方法 | |
| Faloni et al. | Mecanismos celulares e moleculares do estrógeno na reabsorção óssea | |
| US10045954B2 (en) | Use of novel anti-HPV pharmaceutical preparation | |
| US20240238269A1 (en) | Use of 5-nitro-8-hydroxyquinoline | |
| Wang et al. | The effects of obesity surgery on bone metabolism: what orthopedic surgeons need to know | |
| Liu et al. | Association of serum total cholesterol and left ventricular ejection fraction in patients with heart failure caused by coronary heart disease | |
| US20180042943A1 (en) | Methods for modulating bone density | |
| De Leo et al. | Combination of statins and hormone replacement therapy in postmenopausal women is associated with increased bone mineral density | |
| JP2018534291A (ja) | マンモグラフィ乳房密度及び／又は乳癌のリスクを低下させる方法 | |
| US20130143848A1 (en) | Use of megestrol acetate for improving heart function and the treatment of heart insufficiency | |
| US20250288632A1 (en) | Viral Entry Inhibitors Derived From Botanicals | |
| WO2004096278A1 (ja) | アディポネクチン産生増強剤 | |
| JP5930784B2 (ja) | サーチュイン遺伝子活性化剤 | |
| CN110876766A (zh) | 牡丹籽油在制备改善男性骨生物力学性能的药品及保健食品的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140203 |